Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 257-270 , July 2010

Altered Biodistribution and Incidental Findings on Myocardial Perfusion Imaging

  • Murthy Chamarthy, MD
    • ,
  • Mark I. Travin, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark I. Travin, MD, Department of Nuclear Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467-2490

References 

  1. Klocke FJ, Baird MG, Bateman TM, et al. ACC:/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol. 2003;42:1318–1333
  2. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171–185
  3. Lee TH, Udelson JE. Nuclear cardiology: Guidelines. In:  Libby P,  Bonow RO,  Mann DL,  Zipes DP,  Braunwald E editor. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. (ed 8). Philadelphia: W. B. Saunders; 2008;
  4. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900–2906
  5. Hendel RC, Gibbons RJ, Bateman TM. Use of rotating (cine) planar images in the interpretation of a tomographic myocardial perfusion study. J Nucl Cardiol. 1999;6:234–240
  6. Rehm PK, Atkins FB, Ziessman HA, et al. Frequency of extra-cardiac activity and its effect on Tc99m-MIBI cardiac SPET interpretation. Nucl Med Commun. 1996;17:851–856
  7. Williams KA, Hill KA, Sheridan CM. Noncardiac findings on dual-isotope myocardial perfusion SPECT. J Nucl Cardiol. 2003;10:395–402
  8. Raza M, Panjrath GS, Haider A, et al. Extracardiac abnormalities on myocardial perfusion imaging. J Nucl Cardiol. 2005;12:S36;(abstr)
  9. Gedik GK, Ergun EL, Aslan M, et al. Unusual extracardiac findings detected on myocardial perfusion single photon emission computed tomography studies with Tc-99m sestamibi. Clin Nucl Med. 2007;32:920–926
  10. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors (Preliminary results and comparison with Tl-201). Clin Nucl Med. 1992;17:171–176
  11. Aktolun C, Bayhan H, Pabuccu Y, et al. Assessment of tumor necrosis and detection of mediastinal lymph node metastasis in bronchial carcinoma with technetium-99m sestamibi imaging: Comparison with CT scan. Eur J Nucl Med. 1994;21:973–979
  12. Hindie E, Melliere D, Perlemuter L, et al. Primary hyperparathyroidism: Higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Radiology. 1997;204:221–228
  13. Van Kriekinge SD, Germano G, Forscher C, et al. Tumor quantitation and monitoring in whole-body planar technetium-99msestamibi imaging. J Nucl Med. 1997;38:356–361
  14. Kinuya S, Yokoyama K, Watanabe N, et al. Early response of tumour to radiotherapy should be assessed by both uptake and retention of single photon tracers: In vitro analysis with 201Tlchloride, 99Tcm-sestamibi and 99Tcm-tetrofosmin in human bladder cancer cells and human leukocytes. Nucl Med Commun. 1999;20:581–588
  15. Maffioli L, Steens J, Pauwels E, et al. Applications of 99m Tc-sestamibi in oncology. Tumori. 1996;82:12–21
  16. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis-(alkylisonitrile) technetium-99m complexes. J Nucl Med. 1990;31:1166–1167
  17. Fenlon HM, Phelan NC, O'Sullivan P, et al. Benign versus malignant breast disease: Comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography. Radiology. 1997;205:214–220
  18. Caner B, Kitapci M, Unlu M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. J Nucl Med. 1992;33:319–324
  19. Fukushima K, Kono M, Ishii K, et al. Technetium-99m methoxyisobutylisonitrile single-photon emission tomography in hepatocellular carcinoma. Eur J Nucl Med. 1997;24:1426–1428
  20. Chatziioannou SN, Alfaro-Franco C, Moore WH, et al. The significance of incidental noncardiac findings in Tc-99m sestamibi myocardial perfusion imaging: Illustrated by a case. Tex Heart Inst J 26:229-231; 1999;
  21. Klain M, Maurea S, Lastoria S, et al. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med. 1995;36:2248–2251
  22. Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m tetrofosmin whole body scintigraphy in the follow-up differentiated thyroid carcinoma. J Nucl Med. 1997;38:348–352
  23. Seabold JE, Gurll N, Schurrer ME, et al. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med. 1999;40:1434–1440
  24. Sundram FX, Mack P. Evaluation of thyroid nodules for malignancy using 99Tcm-sestamibi. Nucl Med Commun. 1995;16:687–693
  25. Alonso O, Lago G, Mut F, et al. Thyroid imaging with Tc-99m MIBI in patients with solitary cold single nodules on pertechnetate imaging. Clin Nucl Med. 1996;21:363–367
  26. Watanabe N, Hirano T, Fukushima Y, et al. Esophageal cancer detection with Tc-99m tetrofosmin SPECT. Clin Nucl Med. 1997;22:431–433
  27. Ziegels P, Nocaudie M, Huglo D, et al. Comparison of technetium-99m-methoxy-isobutylisonitrile and gallium-67-citrate scanning in assessment of lymphomas. Eur J Nucl Med. 1995;22:126–131
  28. Abdel-Dayem HM, Naddaf SY, Omar WS, et al. Delayed positive thallium uptake in large B-cell non-Hodgkin's malignant lymphoma. J Nucl Med. 1997;38:1213–1215
  29. Matsui R, Komori T, Narabayashi I, et al. Tc-99m sestamibi uptake by malignant lymphoma and slow washout. Clin Nucl Med. 1995;20:352–356
  30. Soderlund V, Jonsson C, Bauer HC, et al. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med. 1997;38:682–686
  31. Ramanna L, Waxman A, Binney G, et al. Thallium-201 scintigraphy in bone sarcoma: Comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med. 1990;31:567–572
  32. Kunisada T, Ozaki T, Kawai A, et al. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: Angiography compared with thallium-201 scintigraphy. Cancer. 1999;86:949–956
  33. Valdes Olmos RA, Koops W, Loftus BM, et al. Correlative 201Tl SPECT, MRI and ex vivo 201Tl uptake in detecting and characterizing cervical lymphadenopathy in head and neck squamous cell carcinoma. J Nucl Med. 1999;40:1414–1419
  34. Yigitbasi OG, Tutus A, Bozdemir K, et al. 201Tl imaging for differentiating between malignant and benign neck masses. Nucl Med Commun. 1998;19:555–560
  35. Henzlova MJ, Cerqueira MD, Hansen CL, et al. ASNC imaging guidelines for nuclear cardiology procedures: Stress protocols and tracers. J Nucl Cardiol 16; 2009;
  36. Athar H, Heller G. Basic principles of flow tracers. In:  Heller GV,  Mann A,  Hendel RC editor. Nuclear Cardiology: Technical Applications. New York: McGraw-Hill; 2008;
  37. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol. 2004;11:71–86
  38. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med. 1999;29:221–236
  39. Chin BB, Zukerberg BW, Buchpiguel C, et al. Thallium-201 uptake in lung cancer. J Nucl Med. 1995;36:1514-1510
  40. Nakada K, Katoh C, Morita K, et al. Relationship among 201T1 uptake, nuclear DNA content and clinical behavior in metastatic thyroid carcinoma. J Nucl Med. 1999;40:963–967
  41. Piwnica-Worms DP, Kronauge JF, LeFurgey A, et al. Mitochondrial localization and characterization of 99Tc-sestamibi in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging. 1994;12:641–652
  42. Mansi L, Rambaldi PF, Cuccurullo V, et al. Diagnostic and prognostic role of 99m–Tc-tetrofosmin in breast cancer. Q J Nucl Med. 1997;41:239–250
  43. Fiskum G (ed): Mitochondrial Physiology and Pathology. New York, Van Nostrand Reinhold, 1986
  44. Heller GV. Tracer selection with different stress modalities based on tracer kinetics. J Nucl Cardiol. 1996;3(suppl 6):S15–S21
  45. Coakley AJ, Kettle AG, Wells CP, et al. 99mTcsestamibi: A new agent for parathyroid imaging. Nucl Med Commun. 1989;10:791–794
  46. O'Doherty MJ, Kettle AG, Wells P, et al. Parathyroid imaging with technetium-99m-sestamibi: Preoperative localization and tissue uptake studies. J Nucl Med. 1992;33:313–318
  47. Taillefer R, Roidoux A, Lambert R, et al. Technetium-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med. 1995;36:1758–1765
  48. Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med. 1997;27:40–54
  49. Lee VW, Antonacci V, Tilak S, et al. Intracranial mass lesions: Sequential thallium and gallium scintigraphy in patients with AIDS. Radiology. 1999;211:507–512
  50. Taillefer R, Robidoux A, Turpin S, et al. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med. 1998;39:459–464
  51. Taillefer R. The role of 99mTc sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 1999;29:16–40
  52. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: An indicator of breast cancer invasiveness. Eur J Nucl Med. 1994;21:984–987
  53. Waxman AD. The role of 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med. 1997;27:40–54
  54. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up. J Nucl Med. 1995;36:1784–1789
  55. Lind P, Umschaden HW, Forsthuber E, et al. Scintimammography using Tc-99m tetrofosmin. Acta Med Austriaca. 1997;24:50–54
  56. Bongers V, Borel Rinkes IH, Sie-Go DM, et al. Detection of malignant breast tumours in dense breast tissue: Results of 99mTctetrofosmin scintimammography related to surgery. Eur J Surg Oncol. 1999;25:152–156
  57. Bom HS, Kim YC, Song HC, et al. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med. 1998;39:91–94
  58. Nishiyama Y, Kawasaki Y, Yamamoto Y, et al. Technetium-99m-MIBI and thallium-201 scintigraphy of primary lung cancer. J Nucl Med. 1997;38:1358–1361
  59. Suga K, Kume N, Nishigauchi K, et al. 201Tl SPECT as an indicator for early prediction of therapeutic effects in patients with non-small cell lung cancer. Ann Nucl Med. 1998;12:355–362
  60. Takekawa H, Shinano H, Tsukamoto E, et al. Technetium-99m tetrofosmin imaging of lung cancer: Relationship with histopathology. Ann Nucl Med. 1999;13:71–75
  61. Kao CH, Ho YJ, Shen YY, et al. Evaluation of chemotherapy response in patients with small cell lung cancer using technetium-99m-tetrofosmin. Anticancer Res. 1999;19:2311–2315
  62. Kashitani N, Eda R, Masayoshi T, et al. Lobar extent of pulmonary lymphangitic carcinomatosis (Tl-201 chloride and Tc-99m MIBI scintigraphic findings). Clin Nucl Med. 1996;21:726–729
  63. Aktolun C, Demirel D, Kir M, et al. Technetium-99m-MIBI and thallium-201 uptake in pulmonary actinomycosis. J Nucl Med. 1991;32:1429–1431
  64. Onsel C, Sonmezoglu K, Camsari G, et al. Technetium-99m-MIBI scintigraphy in pulmonary tuberculosis. J Nucl Med. 1996;37:233–238
  65. Lamont AE, Joyce JM, Grossman SJ. Acute cholecystitis detected on a Tc-99m sestamibi myocardial imaging. Clin Nucl Med. 1996;21:879
  66. Iagaru A, Hachamovitch R, Colletti PM, et al. Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy. J Nucl Cardiol. 2006;13:719–721
  67. Pusuwan P, Ratanamart V, Suwanagool P, et al. Ectopic parathyroid imaging With Tc-99m sestamibi. Clin Nucl Med. 1996;21:74
  68. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer. 2003;10:309–322
  69. Slavin JD, Engin IO, Spencer RP. Retrocardiac uptake of Tc-99m sestamibi: Manifestation of a hiatal hernia. Clin Nucl Med. 1998;23:239–240
  70. Ghanbarinia A, Chandra S, Chhabra K, et al. Renal abnormalities as incidental findings on myocardial single photon emission computed tomography perfusion imaging. Nucl Med Commun. 2008;29:588–592
  71. Raza M, Meesala M, Panjrath G, et al. Abnormal photopenic area on nuclear perfusion imaging. J Nucl Cardiol. 2005;12:607–609
  72. Hurwitz GA, Duan HY, Blais M, et al. An atlas of renography with Tc-99m sestamibi: Comparison with Tc-99m DTPA. Clin Nucl Med. 1995;20:821–829
  73. DePuey EG, Garcia EV. Optimal specificity of thallium-201 SPECT through recognition of imaging artifacts. J Nucl Med. 1989;30:441–449
  74. Cullom SJ. Artifacts and quality control for myocardial perfusion SPECT including attenuation correction. In:  Heller GV,  Mann A,  Hendel RC editor. Nuclear Cardiology: Technical Applications. New York: McGraw-Hill; 2008;
  75. Germano G, Chua T, Kiat H, et al. A quantitative phantom analysis of artifacts due to hepatic activity in technetium-99m myocardial perfusion SPECT studies. J Nucl Med. 1994;35:356–359
  76. Folks R. Myocardial SPECT processing. In:  Heller GV,  Mann A,  Hendel RC editor. Nuclear Cardiology: Technical Applications. New York: McGraw-Hill; 2008;
  77. Ibrahim DY, DiFilippo FP, Steed JE, et al. Optimal SPECT processing and display: Making bad studies look good to get the right answer. J Nucl Cardiol. 2006;13:855–866
  78. Williams KA, Schneider CM. Increased stress right ventricular activity on dual isotope perfusion SPECT (A sign of multivessel and/or left main coronary artery disease). J Am Coll Cardiol. 1999;34:420–427
  79. Pereira N, Klutz W, Fox R, et al. Identification of severe right ventricular dysfunction by technetium-99m-sestamibi gated SPECT imaging. J Nucl Med. 1997;38:254–256
  80. McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996;78:469–473
  81. Hansen CL, Goldstein RA, Akinboboye OO, et al. Myocardial perfusion and function: Single photon emission computed tomography. J Nucl Cardiol. 2007;14:e39–e60
  82. Van Kiat H, Train KF, Freidman JD, et al. Quantitative stress-redistribution thallium-201 SPECT using prone imaging (Methodological development and validation). J Nucl Med. 1992;33:1509–1515
  83. Segall G, Davis M. Prone versus supine thallium myocardial SPECT: A method to decrease artifactual inferior wall defects. J Nucl Med. 1989;30:548–555
  84. Pitman AG, Kalff V, Van Every B, et al. Contributions of subdiaphragmatic activity, attenuation, and diaphragmatic motion to inferior wall artifact in attenuation-corrected Tc-99m myocardial perfusion SPECT. J Nucl Cardiol. 2005;12:401–409
  85. Bateman TM, Cullom SJ. Attenuation correction single-photon emission computed tomography myocardial perfusion imaging. Semin Nucl Med. 2005;35:37–51

PII: S0001-2998(10)00020-6

doi: 10.1053/j.semnuclmed.2010.03.005

Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 257-270 , July 2010

Article Tools

* Image Usage & Resolution